According to Irvine, the group of candidates for FLG replacement therapy would include patients with FLG mutations, patients with variation in FLG repeat numbers, intra-genetic copy number variation, patients with secondary reduced FLG (acquired deficiency), severe and persistent type of AD that have allergic sensitization and in the future could develop asthma, and patients with genodermatoses (93). This evidence concerns the gene FLG and Alzheimer disease.